Clinical Trials · NCT07866066
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Amgen
- Enrollment
- 1,300
- Start date
- Nov 2026
- Locations
- See registry
- Primary endpoint
- Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority]